United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna

Pfizer and Moderna vaccines 80% effective at preventing COVID-19 after one shot, CDC says

Covid-19 vaccine stocks tumbled Monday despite a real-world study showing Moderna's and Pfizer's two-dose coronavirus vaccines are 80% effective after the first dose. The post CDC Head Expresses Sense Of 'Impending Doom' Despite New Vaccine Study appeared first on Investor's Business Daily.

CDC Head Expresses Sense Of 'Impending Doom' Despite New Vaccine Study

The study shows the vaccines prevent all coronavirus infections, not just symptomatic ones.

CDC: Pfizer And Moderna Vaccines Could Significantly Cut Down On Coronavirus Transmission

The two-dose COVID-19 vaccines from Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX) and Moderna Inc (NASDAQ: MRNA) lower the risk for infection by up to 90%, according to data released by the U.S. Centers for Disease Control and Prevention. The study was released in Morbidity and Mortality Weekly Report, an online journal published by the Centers for Disease Control and Prevention.

CDC New Study Shows Pfizer, Moderna COVID-19 Shots 90% Effective Against Infection In Real-World Setting

A single dose of Pfizer or Moderna's Covid-19 vaccines was 80% effective in preventing infections, according to a new CDC study.

One dose of Pfizer or Moderna vaccines was 80% effective in preventing Covid in CDC study of health workers

Enterprise Products Partners

AbbVie

You don't have to sacrifice growth for great dividend yields with these stocks.

3 High-Yield Dividend Stocks With Solid Growth Prospects

This COVID Giant's Shares Are Lagging Behind Rivals -- Here's Why

Pfizer (PFE) and Eli Lilly receive FDA Joint Advisory Committee's vote results for tanezumab being developed for treating osteoarthritis pain. The committee voted 1 in favor and 19 against tanezumab.

Pfizer (PFE) Gets Unfavorable Votes from FDA Panel for Tanezumab

Abbott Labs

Johnson & Johnson

These stocks should still be winners long after the pandemic is over.

Got $1,400? 3 COVID Stocks to Buy and Hold for the Long Term

Eli Lilly

An expert panel of the U.S. Food and Drug Administration has rejected Pfizer Inc. (NYSE: PFE) and Eli Lilly and Company's (NYSE: LLY) application to approve their experimental drug for the treatment of osteoarthritis pain, citing safety risks and an inadequate plan to manage them. What Happened: The FDA's Joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee voted 19-1 that the drug Tanezumab's risks outweigh its benefits for patients with moderate-to-severe osteoarthritis pain, Pfizer and Eli Lilly said in a statement Thursday.

Pfizer And Eli Lilly's Osteoarthritis Drug Rejected By FDA Panel As Too Risky

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have started clinical trials of their jointly-developed COVID-19 vaccine with children, the companies said in a statement Thursday. What Happened: The vaccine trials involve healthy participants aged 6 months to 11-years and the first participants have already received the shots.

In Key Milestone, Pfizer Begins Testing COVID-19 Vaccine In Children

Pfizer Inc. and Eli Lilly and Co. said Thursday that a joint advisory committee of the U.S. Food and Drug Administration has voted against their investigational tanezumab drug for the treatment of certain types of arthritis in adults when use of other drugs aren't possible. "While we are disappointed with today's outcome, we continue to believe that tanezumab has a positive benefit-risk profile for patients with moderate-to-severe osteoarthritis pain for whom current treatments are ineffective or not appropriate," Ken Verburg, tanezumab development team leader at Pfizer, said in a statement.

Pfizer, Eli Lilly say experimental arthritis drug tanezumab hits FDA snag

NEW YORK & INDIANAPOLIS--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced the outcome of the U.S. Food and Drug Administration (FDA) Joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee on tanezumab. There was a single voting question focused on whether the proposed risk evaluation and mitigation strategy (REMS) for tanezumab will ensure its benefits outweigh its risks, and the Committee voted 1 in favor and 19 aga

Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain

In its plan to test the efficacy of its coronavirus vaccine on children as young as six months old, Pfizer joined other drugmakers in a race toward what would mark a major step in the effort to combat the pandemic.

Pfizer Starts Testing Covid-19 Vaccine On Children Ages 6 Months To 11 Years Old

The U.S. is unlikely to achieve herd immunity until children can get vaccinated, public health officials and infectious disease experts say.

Pfizer begins Covid vaccine trial on infants and young kids

Shares of Pfizer Inc. gained 0.2% in premarket trading on Thursday after the company said peer-reviewed research shows that Ibrance improved survival among about 1,400 breast-cancer patients when used as a first-line therapy in combination with aromatase inhibitor letrozole. Patients who had taken the combination therapy reported 20 months of real-world progression-free survival compared to the roughly 12 months reported by patients taking only letrozole.

Pfizer says Ibrance gives more survival time to some breast-cancer patients

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the peer-reviewed publication of real-world evidence (RWE) demonstrating that first-line therapy with IBRANCE® (palbociclib) in combination with letrozole was associated with improved real-world progression-free survival (rwPFS) and overall survival (OS) in women with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) metastatic breast cancer (mBC) compared with letrozole alone. These findings repre

Real-World Evidence Supports Effectiveness of First-line IBRANCE® (palbociclib) Combination Therapy in HR+, HER2- Metastatic Breast Cancer

Pfizer stock edged higher Wednesday on plans to test a coronavirus pill in healthy adults and to push deeper into messenger RNA vaccines. That reversed from its stock dip on Tuesday.

Pfizer Shrugs Off Drug-Pricing Worries As Two Covid-Tied Themes Emerge

Pfizer (PFE) starts an early-stage U.S. study on an oral COVID-19 antiviral candidate.

Pfizer (PFE) Begins Clinical Study on COVID-19 Antiviral Pill

Myovant Sciences

Myovant Sciences Ltd (NYSE: MYOV) and Pfizer Inc (NYSE: PFE) have announced positive data from the Phase 3 LIBERTY randomized withdrawal study evaluating relugolix combination therapy in women with uterine fibroids. The therapy includes relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg.

Myovant/Pfizer's Relugolix Combo Therapy Shows Sustained Clinical Benefit In Uterine Fibroids

Hong Kong and Macau have temporarily suspended COVID-19 vaccines manufactured by Pfizer Inc (NYSE: PFE)/BioNTech SE (NASDAQ: BNTX) due to packaging defects in a batch of vials. Vials with lot number 210102 were found to have defective packaging, authorities said.

Hong Kong Suspends Pfizer/BioNTech COVID-19 Shots On Loose Caps, Minor Dirt: Report

AstraZeneca

BioNTech SE

Novavax

Viatris

This question has multiple right answers.

Which COVID Vaccine Stock Is the Best Pick?

Vaccine maker BioNTech and its Chinese partner Fosun Pharma say they have found no reason to believe the defect may have caused a safety issue.

Hong Kong Suspends Use Of Pfizer-BioNTech Vaccine Due To Defective Bottle Lids

Dyne Therapeutics

PTC Therapeutics

Avidity Biosciences

Solid Biosciences

Sarepta Therapeutics

Vertex Pharmaceuticals

Edgewise Therapeutics has filed to raise $150 million in an IPO.

Edgewise Therapeutics Proposes Terms For $150 Million IPO

Although there is significant optimism surrounding the coronavirus vaccine rollout, recent developments show that 21 states are actually experiencing an increase in infections, generating concern among researchers and government leaders. To that end, Pfizer announced Tuesday it has commenced an early stage clinical trial of an experimental oral antiviral drug for the coronavirus.

News for Pfizer Stock (PFE)